885 related articles for article (PubMed ID: 15616205)
1. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
[TBL] [Abstract][Full Text] [Related]
2. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
Lieberman DA; Weiss DG;
N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia.
Tagore KS; Lawson MJ; Yucaitis JA; Gage R; Orr T; Shuber AP; Ross ME
Clin Colorectal Cancer; 2003 May; 3(1):47-53. PubMed ID: 12777192
[TBL] [Abstract][Full Text] [Related]
4. A comparison of fecal occult-blood tests for colorectal-cancer screening.
Allison JE; Tekawa IS; Ransom LJ; Adrain AL
N Engl J Med; 1996 Jan; 334(3):155-9. PubMed ID: 8531970
[TBL] [Abstract][Full Text] [Related]
5. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.
Greenberg PD; Bertario L; Gnauck R; Kronborg O; Hardcastle JD; Epstein MS; Sadowski D; Sudduth R; Zuckerman GR; Rockey DC
Am J Gastroenterol; 2000 May; 95(5):1331-8. PubMed ID: 10811348
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
7. Colonoscopic screening of average-risk women for colorectal neoplasia.
Schoenfeld P; Cash B; Flood A; Dobhan R; Eastone J; Coyle W; Kikendall JW; Kim HM; Weiss DG; Emory T; Schatzkin A; Lieberman D;
N Engl J Med; 2005 May; 352(20):2061-8. PubMed ID: 15901859
[TBL] [Abstract][Full Text] [Related]
8. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings.
Imperiale TF; Wagner DR; Lin CY; Larkin GN; Rogge JD; Ransohoff DF
N Engl J Med; 2000 Jul; 343(3):169-74. PubMed ID: 10900275
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
[TBL] [Abstract][Full Text] [Related]
10. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
11. Colocare self-test versus Hemoccult II Sensa for fecal occult blood testing.
Foliente RL; Wise GR; Collen MJ; Abdulian JD; Chen YK
Am J Gastroenterol; 1995 Dec; 90(12):2160-3. PubMed ID: 8540507
[TBL] [Abstract][Full Text] [Related]
12. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
Haug U; Hundt S; Brenner H
Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
[TBL] [Abstract][Full Text] [Related]
13. Improved fecal DNA test for colorectal cancer screening.
Itzkowitz SH; Jandorf L; Brand R; Rabeneck L; Schroy PC; Sontag S; Johnson D; Skoletsky J; Durkee K; Markowitz S; Shuber A
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):111-7. PubMed ID: 17161655
[TBL] [Abstract][Full Text] [Related]
14. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380.
Lieberman DA; Weiss DG; Bond JH; Ahnen DJ; Garewal H; Chejfec G
N Engl J Med; 2000 Jul; 343(3):162-8. PubMed ID: 10900274
[TBL] [Abstract][Full Text] [Related]
15. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
[TBL] [Abstract][Full Text] [Related]
16. Patient perceptions of stool-based DNA testing for colorectal cancer screening.
Schroy PC; Heeren TC
Am J Prev Med; 2005 Feb; 28(2):208-14. PubMed ID: 15710277
[TBL] [Abstract][Full Text] [Related]
17. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.
Khalid-de Bakker CA; Jonkers DM; Sanduleanu S; de Bruïne AP; Meijer GA; Janssen JB; van Engeland M; Stockbrügger RW; Masclee AA
Cancer Prev Res (Phila); 2011 Oct; 4(10):1563-71. PubMed ID: 21750209
[TBL] [Abstract][Full Text] [Related]
18. Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history.
Rex DK; Lehman GA; Ulbright TM; Smith JJ; Pound DC; Hawes RH; Helper DJ; Wiersema MJ; Langefeld CD; Li W
Am J Gastroenterol; 1993 Jun; 88(6):825-31. PubMed ID: 8503374
[TBL] [Abstract][Full Text] [Related]
19. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
[TBL] [Abstract][Full Text] [Related]
20. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
